The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors.
about
Role of gonadotropin-releasing hormone (GnRH) in ovarian cancerIntrathymic function of the human cortical epithelial cell surface antigen gp200-MR6: single-chain antibodies to evolutionarily conserved determinants disrupt mouse thymus developmentLeuprorelin acetate long-lasting effects on GnRH receptors of prostate cancer cells: an atomic force microscopy study of agonist/receptor interactionLHRH-conjugated lytic peptides directly target prostate cancer cells.Luteinizing hormone-releasing hormone (LHRH) receptors in the neuroendocrine-immune network. Biochemical bases and implications for reproductive physiopathology.Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cells.Interleukin-4 and breast cancer.Hormonal management of prostate cancer.Ligand-targeted theranostic nanomedicines against cancerInduction of transforming growth factor beta in hormonally treated human prostate cancer.Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline.Selection and characterization of mammalian cell lines with stable over-expression of human pituitary receptors for gonadoliberin.Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues.Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumorsLuteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?Differential signaling of the GnRH receptor in pituitary gonadotrope cell lines and prostate cancer cell lines.Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145.Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines.Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines.Inhibition of growth and enhancement of differentiation of colorectal carcinoma cell lines by MAb MR6 and IL-4.Growth inhibition of human prostate tumor cells by an agonist of gonadotrophin-releasing hormone.Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors.Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice.The current status of scientific research and hormonal treatments for carcinoma of the prostate.Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.Gonadotropin-releasing hormone receptor expression in the human prostate.Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors.GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.The clinical implications of the difference between castration, gonadotrophin releasing-hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate.Extrapituitary gonadotropin-releasing hormone (GnRH) binding sites in goldfish.Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.Cytoplasmic versus nuclear localization of Fos-related proteins in the frog, Rana esculenta, testis: in vivo and direct in vitro effect of a gonadotropin-releasing hormone agonist.
P2860
Q21245571-519B7349-42A7-4C94-ACEB-75ECBBFE258FQ24643035-B92767C2-4EEC-4955-B0DA-C0FC2CB73D3DQ28484928-A5060571-CDDF-4645-94A4-36FB340C5AC0Q30497581-EEB41061-A5BB-49B6-B021-7C9446223E88Q33495924-EB4D5447-A701-4A63-892C-D1B15D22E034Q33889649-C0EB1AB6-D759-439F-A60A-79D913B800F4Q34058956-2C32A5B5-4FAA-4D69-8D55-E71FBB95A708Q35178831-9E0AC31D-12C5-4CE4-BC63-01778EF1E99CQ35895637-4D7C6309-C251-47E9-A44F-FA0E744B74CCQ35978065-2F6A5E1A-84C9-41D1-90B4-13ACB897E8B7Q35997236-21EAE093-1DDA-478B-84A0-C974406AFE41Q36202016-C71632B7-8859-4C5F-A912-068A3E7E971DQ36616126-E2C7CF53-0B94-4F53-A099-EF04C77597D1Q36691229-0AF2C3F7-5D01-4896-9D4C-CF9218EA9A9BQ37271561-43EC47E2-552D-49E5-BDA0-D01BB4CEB253Q37311388-6AA60D55-B971-4696-B08C-93957ED70AC8Q37387473-6489164D-AD38-4022-B441-D234183A8814Q37412449-83AC6F8B-D32D-42E1-9F17-A9AA9BA07F5BQ38082516-D1D5C597-7FDE-4077-BABB-0033117BB287Q39199813-36257306-508A-46C4-A280-46B3F6967C80Q39267156-71AADDDD-CC23-4C53-BFBB-32B3972C1B6AQ39494573-B1C53050-F387-408C-8169-6F4EA93CFFB3Q40371237-F58525A4-0369-41B7-9F40-676820DE3637Q40883084-B5296E0F-5A13-4691-B47D-15AF6EE8F635Q41102499-0A3EE74C-9D58-4591-9251-54A04CD4B385Q41102503-D1EF2F30-EF87-4D97-AFF7-3676E89ECE7BQ41109872-8278EDEB-36D5-4AFE-8ECE-7EB19E253477Q41354135-E19848EB-671F-4B27-B880-2FEEC1786887Q41431913-CBC76ACD-9960-48D2-BA9C-86B318CD1FBCQ41438321-933E33B1-AF98-4E4B-90C0-C102917BE44FQ42268500-3A8C90C1-BC08-441B-84E6-11880982917EQ42372263-CCD91521-C802-4DE1-A34D-DE66B4CE9AD9Q42476712-86BBB7BC-93D1-4E8C-B94F-C2282AF68D3DQ42505574-BFE26984-59BB-4BDB-A5EF-C057A88EEF24Q42972866-AB84786A-1D3B-483C-B5EC-1E471909D937Q43757460-B2FE3E92-68EE-4858-92AF-66E3F9C4DFEDQ44311577-B5B529E8-0C7B-496F-8566-8C2F697AF844Q48250864-F3A1813A-1D56-443D-8624-42CD9702D6F8Q48656281-F88A36A0-03A4-4548-B8DC-0B9C1B8E0F81Q54787676-B89036E7-A2F8-40CF-B3C5-F7F7C6BD542A
P2860
The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
The effects of gonadotrophin r ...... ugh specific tumour receptors.
@en
type
label
The effects of gonadotrophin r ...... ugh specific tumour receptors.
@en
prefLabel
The effects of gonadotrophin r ...... ugh specific tumour receptors.
@en
P2093
P2860
P356
P1476
The effects of gonadotrophin r ...... ugh specific tumour receptors.
@en
P2093
P2860
P2888
P356
10.1038/BJC.1990.236
P407
P577
1990-07-01T00:00:00Z